RIC LEADERSHIP

Kevin Holman, MBA, RAC
RIC BOARD CHAIR
Johnson & Johnson
Innovative Medicine

Kishore Gopu, MS, MBA
RIC BOARD VICE-CHAIR
Teva Pharmaceuticals

Kal Elhoregy, RPh, PA
RIC BOARD TREASURER
Communications & Marketing Working Group Lead
Amneal Pharmaceuticals

Michael Cheung, DHSc, MS
RIC BOARD SECRETARY
Bristol-Myers Squibb

Ron Selders
RIC BOARD MEMBER
Viatris

Cherie Johnson
RIC BOARD MEMBER
Jazz Pharmaceuticals

Tina Latch
RIC BOARD MEMBER
Endo USA, Inc.

Jamie Wilkins
RIC BOARD MEMBER
Education/Certification Working Group Co-Lead
Pfizer Inc.

Carmit Strauss, PharmD
RIC BOARD MEMBER
Takeda

FOUNDING MEMBER COMPANIES

Amneal Pharmaceuticals
Bristol-Myers Squibb
The Janssen Pharmaceutical Companies of Johnson & Johnson
Jazz Pharmaceuticals
Teva Pharmaceuticals
Viatris

ric
REMS Industry Consortium®
Innovating Patient Safety. Mitigating Risk.

1120 Route 73, Suite 200
Mount Laurel, NJ 08054

856.380.6894 | info@remsconsortium.org
remsconsortium.org

JOIN LEADERS IN REMS

AbbVie
Alexion - Astra Zeneca Rare Disease Unit
Amneal Pharmaceuticals
Apcer Life Sciences
Apellis Pharmaceuticals, Inc.
Apotex
Ascend Laboratories LLC, a subsidiary of Alkem Laboratories Ltd
Avadel Pharmaceuticals
Axian Consulting Ltd
BioMarin
Bristol Myers Squibb
Chinook Therapeutices, Inc.
Compass Pathways
Compliance Architects LLC
ConnectiveRx
Endo Pharmaceuticals
Gilead Sciences
GSK
Hikma Pharmaceuticals USA Inc.
Integrated Pharmacy Solutions
Invaryant LLC
Jazz Pharmaceuticals
Johnson & Johnson Innovative Medicine
KPMG
Maryann Major Inc.
Metis Consulting Services, Inc.
MMS Holdings, Inc.
MVG Consulting Services Inc.
North Highland
Novartis
Pfizer Inc.
PPD
Quandary Peak Research, Inc.
Regeneron
Sanofi
Shephard Safety Services at Two Labs
Syneos Health
Takeda
Tasman Pharma Inc.
Teva Pharmaceuticals
UBC
UCB, Inc.
United BioSource LLC
Venebio Group, LLC
Viatris

ric
REMS Industry Consortium®
Innovating Patient Safety. Mitigating Risk.

Innovating Patient Safety. Mitigating Risk.

BECOME A LEADER IN REMS

Join the REMS Industry Consortium today!

WHY RIC?

RIC stands as a trusted and reliable source, offering the latest insights into cutting-edge REMS (Risk Evaluation and Mitigation Strategies) issues. Our consortium membership is comprised of drug and biopharmaceutical companies, as well as REMS program service providers, that are building a bridge for open communication and collaboration among many stakeholders, including our membership, healthcare community members, and FDA.

We unite industry stakeholders in a collective effort to address challenges, sharing invaluable experiences and best practices to guide your REMS programs. By joining RIC, you gain the opportunity to network and build lasting relationships with REMS industry professionals. Most importantly, you become an active contributor to advancing the REMS industry, making a significant impact on the field.

BENEFITS AS A RIC MEMBER

- **Interact directly with the FDA to find ways to cut down the approval time for REMS innovation as the industry's unified voice**
- **Contribute to REMS industry innovation**
- **Network with REMS industry professionals at programs like the RIC Annual Meeting**
- **Exclusive knowledge-sharing opportunities**
- **Opportunity to help develop leading-edge REMS education**
- **Generate cost savings with hours of free consultation**

HAVE YOUR VOICE HEARD THROUGH RIC WORKING GROUPS

BEST PRACTICES

Leverage industry experience to suggest ways to streamline REMS program elements and enhance efficiencies for stakeholders.

COMMUNICATIONS & MARKETING

Conducts qualitative review and feedback for materials produced by all working groups. Develops RIC communications plan, oversight of RIC branding/messaging, and identifies topics for white papers and supports publication.

EDUCATION/CERTIFICATION

Develops educational resources and RIC credentialing programs for various stakeholders, which includes the development of core curriculum and ancillary training modules.

FDA INTERACTIONS

Seeks to engage with FDA by responding to FDA outreach on REMS-related initiatives and preparing recommendations for FDA on ideas generated by working groups and task forces.

INNOVATION & TECHNOLOGY

Explores ways to increase vendor capabilities. Identifies tactics to spur innovation and technology improvement.